These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 28647100)

  • 1. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
    Proctor L; Pradhan M; Leung S; Cheng A; Lee CH; Soslow RA; Gilks CB; Talhouk A; McAlpine JM; Danielsen HE; Hoang LN
    Gynecol Oncol; 2017 Sep; 146(3):596-602. PubMed ID: 28647100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
    Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
    Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
    Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.
    Hoang LN; Kinloch MA; Leo JM; Grondin K; Lee CH; Ewanowich C; Köbel M; Cheng A; Talhouk A; McConechy M; Huntsman DG; McAlpine JN; Soslow RA; Gilks CB
    Am J Surg Pathol; 2017 Feb; 41(2):245-252. PubMed ID: 28079598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
    Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
    Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
    Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
    Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.
    Raffone A; Travaglino A; Gabrielli O; Micheli M; Zuccalà V; Bitonti G; Camastra C; Gargiulo V; Insabato L; Zullo F
    Arch Gynecol Obstet; 2021 Jun; 303(6):1393-1400. PubMed ID: 33754186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients.
    Sinicrope FA; Rego RL; Halling KC; Foster N; Sargent DJ; La Plant B; French AJ; Laurie JA; Goldberg RM; Thibodeau SN; Witzig TE
    Gastroenterology; 2006 Sep; 131(3):729-37. PubMed ID: 16952542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization in the prediction of disease extent in endometrial carcinoma.
    Kolehmainen AM; Pasanen AM; Koivisto-Korander RL; Bützow RC; Loukovaara MJ
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():478-483. PubMed ID: 33189427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical application of TCGA molecular classification in endometrial endometrioid carcinoma].
    Du NN; Liu Y; Ren CX; Wang YX; Du J; Yang J; Liu CR
    Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):596-603. PubMed ID: 31422589
    [No Abstract]   [Full Text] [Related]  

  • 11. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women.
    He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T
    Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathological characterization of ProMisE molecular groups of endometrial cancer.
    Raffone A; Travaglino A; Mascolo M; Carotenuto C; Guida M; Mollo A; Insabato L; Zullo F
    Gynecol Oncol; 2020 Apr; 157(1):252-259. PubMed ID: 31932106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical factors as prognostic variables among molecular subgroups of endometrial cancer.
    Kolehmainen A; Pasanen A; Tuomi T; Koivisto-Korander R; Bützow R; Loukovaara M
    PLoS One; 2020; 15(11):e0242733. PubMed ID: 33232359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
    Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
    Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
    Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
    Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial neoplasia: prognostic significance of ploidy status.
    Evans MP; Podratz KC
    Clin Obstet Gynecol; 1996 Sep; 39(3):696-706. PubMed ID: 8862893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
    Lukes AS; Kohler MF; Pieper CF; Kerns BJ; Bentley R; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC; Berchuck A
    Cancer; 1994 May; 73(9):2380-5. PubMed ID: 7909491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of DNA content assessment in endometrial cancer.
    Mauland KK; Wik E; Salvesen HB
    Cytometry B Clin Cytom; 2014 May; 86(3):154-63. PubMed ID: 24532190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in surgical stage I endometrial carcinoma.
    Lundgren C; Auer G; Frankendal B; Nilsson B; Nordström B
    Acta Oncol; 2004; 43(1):49-56. PubMed ID: 15068320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential impact of clinicopathological risk factors within the 2 largest ProMisE molecular subgroups of endometrial carcinoma.
    Pasanen A; Loukovaara M; Ahvenainen T; Vahteristo P; Bützow R
    PLoS One; 2021; 16(9):e0253472. PubMed ID: 34473724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.